This excerpt taken from the ELN 6-K filed Sep 29, 2009.
The Johnson & Johnson Transaction resulted in the assignment of our AIP collaboration agreement with Wyeth and associated business, which primarily constitutes intellectual property, to Janssen AI. While we have a 49.9% interest in Janssen AI, Johnson & Johnson exercises effective control over Janssen AI and consequently over our share of the AIP collaboration. The success of the AIP will be dependent, in part, on the efforts of Johnson & Johnson. The interests of Johnson & Johnson may not be aligned with our interests. Our ability to influence Janssen AI will be very limited. The failure of Johnson & Johnson to pursue the development and commercialization of AIP products in the same manner we would have pursued such development and commercialization could materially and adversely affect us.